Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the pharmacokinetic comparability between TAK-881 and HYQVIA when given as subcutaneous injections for maintenance therapy in adults with chronic inflammatory demyelinating polyradiculoneuropathy CIDP. This phase 3 trial focuses on participants who have been receiving intravenous or subcutaneous immunoglobulin treatments and aims to compare these two treatments in terms of how the body absorbs and processes them. The study includes several phases starting with screening and possibly a ramp-up phase for those switching treatments. Participants already on HYQVIA go directly to that treatment phase, which lasts 18 to 20 weeks depending on dosing intervals. Then all participants switch to TAK-881 for 24 weeks. After this, an extension phase allows continued treatment for up to 3 years, with home infusions permitted and clinic visits spaced between 12 and 24 weeks. Treatments are given by subcutaneous infusion using specialized needle sets. Participants will visit the clinic every 3 or 4 weeks during the initial phases to undergo assessments including blood sampling to measure immunoglobulin G levels at various time points. The study also tracks clinical disability scores, hand grip strength, muscle strength, and adverse events over time. Safety and treatment tolerability are closely monitored throughout the trial. Total participation may last several years including the extension phase.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years with severe uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids and at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, randomized, double-blind study aims to compare tezepelumab with a placebo to better understand its impact on asthma control in this age group. Participants will be randomly assigned in a 21 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo over a 52-week double-blind treatment period. Before treatment, there is a 4 to 6 week screening and run-in period. After the treatment period, a 12-week off-treatment follow-up occurs for those not continuing. Eligible participants may enter an optional 104-week open-label extension to receive tezepelumab with an additional 12-week follow-up after that. During the study, participants will undergo various assessments including lung function tests, asthma symptom tracking, quality of life questionnaires, and blood tests to measure biomarkers and drug levels. Researchers will monitor asthma exacerbations, rescue medication use, and healthcare visits. Safety will be closely observed throughout the study and follow-up periods. Total participation may last over two years for those in the extension phase.
Actively Recruiting
Researchers are evaluating how the study medicine PF-06823859 dazukibart works in adults with active idiopathic inflammatory myopathies, specifically dermatomyositis DM and polymyositis PM. These rare diseases cause muscle inflammation leading to muscle weakness and sometimes skin rash in DM. The study aims to assess the safety and effectiveness of dazukibart compared to placebo in people already receiving stable doses of corticosteroids or immunosuppressants. Participants will be randomly assigned to receive either dazukibart or a placebo via intravenous infusion every 4 weeks, starting from Day 1 to Week 48. Each infusion takes about 1 hour and is administered at the study site. The study uses a double-blind design, meaning neither participants nor researchers know who receives the active drug or placebo, allowing for an unbiased comparison. Participants will be involved in approximately 15 visits over about 13 months. During these visits, researchers will monitor muscle strength, skin symptoms, physical function, fatigue, itch severity, corticosteroid use, and overall improvement using various clinical scales and patient questionnaires. Safety will be closely followed throughout the study. The main outcome measure is the Total Improvement Score TIS evaluated at 24 weeks outside the US and 52 weeks within the US.
Actively Recruiting
Researchers are evaluating the long-term effects of iptacopan in people with C3 glomerulopathy C3G or idiopathic immune-complex-membranoproliferative glomerulonephritis IC-MPGN. This open-label extension study focuses on assessing the safety, tolerability, and sustained efficacy of iptacopan over an extended period, following participants who completed earlier phase 2 or phase 3 studies. The study aims to provide important data to support regulatory submissions and continued access to treatment. Participants receive iptacopan capsules at a dose of 200 mg twice daily. The study includes different groups based on prior study participation and kidney status, including those with native kidneys and kidney transplants, as well as participants from core phase 3 studies who were randomized to placebo or iptacopan. This extension study is planned to continue until iptacopan becomes commercially available, the benefit-risk profile changes, or the program is discontinued, potentially lasting up to approximately 168 months. During the study, participants undergo regular efficacy and safety assessments, including monitoring of renal endpoints, adverse events, vital signs, electrocardiograms, and laboratory tests. Data collected includes urine protein and albumin levels, serum creatinine, estimated glomerular filtration rate, and complement C3 levels. The study expects participants to remain for a minimum of 60 months and up to 84 months, with the goal of understanding long-term treatment effects and tolerability.
Actively Recruiting
Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.
Actively Recruiting
Researchers are conducting a multicenter prospective observational registry to study adults with local complications of acute pancreatitis or postoperative pancreatic fistula. The study aims to evaluate clinical characteristics and treatment outcomes in routine medical care settings. Because these complications are uncommon in individual centers, the study seeks to gather comprehensive data to better understand treatment selections, timing, and results. Participants receive routine clinical management chosen by their treating doctors, which may include conservative care, endoscopic or percutaneous drainage, necrosectomy, stent placement, or surgery when needed. The study does not assign any specific diagnostic or therapeutic interventions but observes treatments as they occur naturally in clinical practice. Throughout the study, data including patient characteristics, imaging findings, treatments, adverse events, recurrences, and outcomes will be collected. The primary goal is to assess clinical success within 180 days after enrollment. Secondary outcomes include technical success of initial interventions, adverse events, need for additional treatment, recurrence, mortality, and healthcare utilization. Participants may be followed for up to 180 days to monitor these outcomes.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the Enzeavour Pancreatic Cancer assay as a screening tool for pancreatic cancer in asymptomatic adults in Japan. This nationwide, multicenter, prospective, single-arm feasibility study aims to assess the detection rate and positive predictive value of this blood-based test in routine health checkups and cancer screening programs. Pancreatic cancer is often diagnosed late, and this study seeks to develop an effective population-based screening strategy. Participants will have blood samples collected during routine health checkups or organized cancer screenings. The Enzeavour assay measures the activity of three specific enzymes at a single-molecule level and combines four biomarkers into a composite score. Those with an Enzeavour Score above 0.369 will be referred for further diagnostic imaging such as MRCP, EUS, or contrast-enhanced CT as needed. This diagnostic work-up follows the initial screening result. Throughout the study, which follows participants for 12 months after the blood draw, researchers will monitor pancreatic cancer detection rates and the assays positive predictive value. Participants will be evaluated through blood tests and any indicated diagnostic imaging. The study will include approximately 10,000 adults and aims to provide real-world data for planning future trials. The total duration of participation varies based on follow-up needs.
Actively Recruiting
Researchers are evaluating the effects of acoramidis in people with transthyretin-type cardiac amyloidosis ATTR-CM, a condition affecting the heart. The study aims to confirm whether acoramidis can prevent the worsening of disease progression markers and assess how these markers reflect disease status. This phase 4 post-marketing study is sponsored by Alexion Pharmaceuticals, Inc. and focuses on real-life treatment outcomes. Participants will take 800 mg of acoramidis twice daily for 18 months. This single-arm, open-label study involves monitoring changes in cardiac biomarkers and clinical features related to ATTR-CM. The study does not include a placebo group, and all participants receive the same treatment throughout the study period. During the study, participants will undergo regular assessments including blood tests for markers like NT-proBNP and high-sensitivity cardiac troponin T, kidney function tests, and questionnaires measuring heart-related quality of life. Researchers will track disease progression over 12 months and follow participants up to 18 months. Safety and treatment effects will be closely monitored throughout this time.
Actively Recruiting
Researchers are evaluating eltrombopag in pediatric patients with aplastic anemia AA who have not previously received Anti-Thymocyte Globulin ATG treatment. This observational, multicenter study aims to confirm the safety and efficacy of eltrombopag when used in this specific patient group. The study focuses on children aged 6 to under 18 years and is sponsored by Novartis Pharmaceuticals. Eltrombopag will be administered following the dosage and administration instructions in the most recent package insert. The study does not involve treatment allocation but observes patients receiving eltrombopag in routine clinical practice. Participants are monitored for up to one year 364 days from the start of eltrombopag treatment, or until hematopoietic stem cell transplantation if it occurs within that year. During the study, participants will be observed for serious adverse events, adverse drug reactions, and hematologic response. Researchers will track changes in blood counts including platelets, hemoglobin, neutrophils, and reticulocytes, as well as transfusion dependence and volume. Safety aspects such as hepatic dysfunction, hematopoietic malignancies, and clonal evolution will also be assessed. The studys primary outcome is the occurrence of serious adverse events within one year.
Actively Recruiting
This research observes patients with BRAF V600E mutation-positive unresectable advanced or recurrent solid tumors, excluding colorectal cancer, to monitor the safety and effectiveness of dabrafenib and trametinib. It is a prospective, multicenter, single-arm, non-interventional observational study that collects real-world data under current medical practices. The study is conducted using an electronic data capture system and aims to gather long-term information especially in pediatric patients. Participants receive dabrafenib and trametinib as prescribed according to the Japanese Package Insert without treatment assignment by the study. Adult patients are observed for one year after starting treatment, while pediatric patients are followed for up to eight years regardless of whether they continue treatment, to collect extensive safety and response data during the reexamination period. The study aims to include approximately 65 adults and about 20 pediatric patients. During the study, researchers collect data on adverse events related to skeletal and sexual maturation in pediatric patients, overall response rate in adults, progression-free survival, changes in height and weight, and other safety outcomes. Data collection occurs throughout the observation periods for both adult and pediatric patients. The study is sponsored by Novartis Pharmaceuticals and is designed to provide important long-term safety and effectiveness information on these medications used in routine care.
1-10 of 13
1